Background: The term rapidly progressive dementia (RPD) may be applied to patients with precipitous declines in cognitive function resulting in dementia within one year or complete incapacitation within two-years of symptom onset. Although most patients present with subacute, progressive declines, selected patients develop complete incapacitation within seven days of symptom onset. The differential diagnosis and clinical characteristics of patients with abrupt-onset dementia are not known.
Method: 187 patients with RPD were prospectively enrolled from February 2016 to September 2023 in a study of RPD at Mayo Clinic (Jacksonville, Florida) and Washington University (Saint Louis, Missouri). Patients with ≤7 days from first symptom to onset of RPD were labelled as abrupt onset. Patient characteristics, results of investigations, and causes of abrupt-onset dementia were further characterized. We further explored the causes of abrupt-onset dementia in the extant literature to refine the differential diagnosis and approach to evaluation and management of these patients.
Result: Two patients in our study of RPD had abrupt-onset RPD (2/187, 1.1%), attributed to autoimmune and vascular. An additional 63 cases were identified through comprehensive meta-narrative review of the literature (40 publications). Causes of abrupt-onset dementia include vascular, infectious, inflammatory, and toxic. Compromise of structures within the Papez circuit was a common unifying feature common across patients with varying etiologies, informing the localization of abrupt-onset dementia. 20% cases had potentially treatment-responsive causes of abrupt-onset dementia.
Conclusion: Cases of abrupt-onset dementia are rare overall and associated with a limited differential diagnosis. Evaluation of patients with abrupt-onset dementia should prioritize testing for vascular, autoimmune, infectious, and toxic causes. Early-recognition of patients with potentially treatment-responsive causes of dementia may promote earlier intervention leading to better outcomes in selected patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.087411 | DOI Listing |
Background: The term rapidly progressive dementia (RPD) may be applied to patients with precipitous declines in cognitive function resulting in dementia within one year or complete incapacitation within two-years of symptom onset. Although most patients present with subacute, progressive declines, selected patients develop complete incapacitation within seven days of symptom onset. The differential diagnosis and clinical characteristics of patients with abrupt-onset dementia are not known.
View Article and Find Full Text PDFFront Neurol
October 2024
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
BMC Geriatr
February 2024
Division of Geriatrics and Gerontology, Johns Hopkins School of Medicine, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Suite 2200, 21224, Baltimore, MD, USA.
Background: Since 2003 when memantine was first approved for use in the management of moderate-severe Alzheimer's dementia, its use has become more widespread and is being explored in other diseases like neuropathic pain, epilepsy, and mood disorders. Our case uniquely highlights two important adverse effects in a patient who overdosed on memantine. One is hypertension, which is easy to overlook as a medication side effect.
View Article and Find Full Text PDFEur Biophys J
July 2018
Department of Physics, ISA 2019, University of South Florida, 4202 East Fowler Ave, Tampa, 33620, FL, USA.
Beta amyloid (A[Formula: see text] ) associated with Alzheimer's disease (AD) leads to abnormal behavior in inhibitory neurons, resulting in hyperactive neuronal networks, epileptiform behavior, disrupted gamma rhythms, and aberrant synaptic plasticity. Previously, we used a dual modeling-experimental approach to explain several observations, including failure to reliably produce action potentials (APs), smaller AP amplitudes, higher resting membrane potential, and higher membrane depolarization in response to a range of stimuli in hippocampal inhibitory neurons from 12- to 16-month-old female AP Pswe/PSEN1DeltaE9 (APdE9) AD mice as compared to age-matched non-transgenic (NTG) mice. Our experimental results also showed that AP initiation in interneurons from APdE9 mice are significantly different from that of NTG mice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!